Since Alzheimer's disease affects over 7 million people in the U.S., potentially doubling to 14 million by 2050, earlier ...

The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s ...

The Food and Drug Administration has cleared the blood test to help diagnose Alzheimer's disease, potentially making it ...

The very first blood test for Alzheimer's disease detection has been green-lit by the US Food and Drug Administration (FDA), ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the ...

The FDA has granted 510(k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s ...

The test is for those aged 55 and older who are already exhibiting signs and symptoms of the disease, the FDA says.

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The Food and Drug Administration has approved the first blood test for diagnosing Alzheimer's disease, the agency announced ...